Streetbeat News

Earnings

EXK

Endeavour Silver Corp. reported its full year 2023 production, totaling 5.7 million ounces of silver and 37,858 ounces of gold, which equates to 8.7 million silver equivalent ounces. The fourth quarter contributed 1.4 million ounces of silver and 9,440 ounces of gold to this total.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 11:55 am

CAH

Cardinal Health has updated its FY24 adjusted EPS guidance to the higher end of the $6.75-$7.00 range, exceeding the $6.95 estimate. The company also plans to execute a new $250M accelerated share repurchase program in Q2. Cardinal Health reiterated its long-term targets, aiming for a 12%-14% growth in adjusted EPS. The update is attributed to strong cash flow generation leading to higher cash balances and favorable fiscal conditions.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 11:52 am

BNTX

BioNTech presented its strategic priorities for 2024 at the J.P. Morgan Healthcare Conference, aiming to have ten or more registrational trials by the end of 2024 and to be commercial-ready by the end of 2025. The company reported an unaudited €17.5 billion in cash and equivalents for 2023 and anticipates revenues of about €3 billion for 2024.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 11:46 am

ES

Eversource Energy (NYSE:ES) is in advanced talks to sell its 50% stake in three offshore wind projects to a global private infrastructure investor. The company will record an impairment charge of $1.4-$1.6 billion in Q4 due to revised construction costs, which will not affect future cash flows or current cash balances. Eversource will provide 2024 earnings guidance and other financial forecasts in an upcoming earnings call.

Portfolio Pulse from Shivani Kumaresan

January 09, 2024 | 11:44 am

NARI

Inari Medical announced preliminary unaudited revenue for Q4 2023 of at least $132M, a 22% increase year-over-year, surpassing the consensus estimate of $130.98M. The company also reported preliminary unaudited revenue for FY23 of at least $493.5M, a 29% increase year-over-year, slightly above the consensus estimate of $492.61M.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 11:35 am

MSM

MSC Industrial Direct Co (NYSE:MSM) reported Q1 adjusted EPS of $1.25, missing the $1.31 estimate, and sales of $954M, below the $972.06M estimate. This reflects a 15.54% decrease in EPS and a 0.39% decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 11:31 am

AYI

Acuity Brands (NYSE:AYI) reported Q1 earnings with an EPS of $3.72, beating estimates by 15.17% but with a revenue decrease of $63.20 million from the previous year. The company had previously beaten EPS estimates last quarter, which did not affect the share price the following day.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 11:10 am

ELTX

Elicio Therapeutics has published data from its Phase 1 AMPLIFY-201 study of ELI-002 2P in solid tumors in Nature Medicine. The results show that ELI-002, as a monotherapy, induced strong and lasting T cell responses and led to tumor biomarker reduction in 84% of patients. This correlated with a median relapse-free survival of 16.3 months. A Phase 2 trial for ELI-002 in pancreatic ductal adenocarcinoma is set to begin in early 2024.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 11:03 am

AYI

Acuity Brands reported Q1 adjusted EPS of $3.72, surpassing the $3.23 estimate by 15.17%, and a 13.07% increase from last year's $3.29 per share. However, sales of $934.70M slightly missed the $935.14M estimate by 0.05%, marking a 6.33% decrease from the previous year's $997.90M.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 11:03 am

BAC

Bank of America Corp (BAC) anticipates a $1.6 billion non-cash, pretax charge in Q4 FY23 due to the phase-out of a Bloomberg interest rate benchmark. The charge is expected to be recouped into interest income mostly by 2026 as BSBY-indexed loans transition to SOFR. The one-time charge has reduced BAC's CET1 ratio by eight basis points. BAC's Q4 FY23 results will be reported on January 12, 2024. BAC shares dropped 0.50% in premarket trading.

Portfolio Pulse from Lekha Gupta

January 09, 2024 | 10:51 am